[A new approach to the treatment of sleep disorders in patients with cerebrovascular diseases].
A positive result has been obtained in treating sleep disorders in patients with chronic vascular affections of the brain with using the drugs donormyl and sonnate-KM [symbol: see text]. Donormyl is recommended for use in sleep disturbances (not very prolonged and not profound insomnia) in a 10-day therapeutic course as a first-choice drug.
Rudenko
A E
AE
Korzhenevskiĭ
L V
LV
Bashkirova
L M
LM
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053961:Azabicyclo Compounds; D002561:Cerebrovascular Disorders / Q000150:complications*; D004319:Doxylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone; D004319:Doxylamine; C035385:doxylamine succinate